PROPRIETARY MEDICAL IMAGING SYSTEM RECEIVES PATENT APPROVAL
SCOTTSDALE, Ariz., June 15, 2022 /PRNewswire/ — Imaging Endpoints (IE), an imaging CRO (iCRO) that provides comprehensive central imaging services and technology solutions throughout the clinical trial process, announced that the United States Patent and Trademark Office (USPTO) has approved the patent for Imaging Endpoints’ Proprietary Medical Imaging System (Patent 11361020).
Imaging Endpoints was issued the patent today, allowing all twenty of the submitted claims for its Proprietary Medical Imaging System that provides an industry-leading approach for optimizing large imaging datasets to enable radiomic and other research. The technology involves the following processes, to be applied in an automated manner to databases containing millions of images:
Imaging Endpoints’ Proprietary System contains multiple interconnecting processes and technological solutions that prioritize efficiency and data security. This new system will work in concert with Imaging Endpoints’ BRAIN (Batched Radiomics AI Network) and Real Intelligence (RI) platforms to enable IE to provide top-tier services as the leader in the analysis of large imaging datasets for radiomics and other research purposes.
“This patent demonstrates our commitment to innovation and our dedication to connecting imaging to the cure™ by developing and applying the most advanced imaging technologies available globally,” said Doug Dean Burkett, PhD, Chief Executive Officer and President at Imaging Endpoints. “We will continue to push the boundaries of imaging science in our mission to revolutionize the data an imaging CRO can provide.”
Learn more about Imaging Endpoints at their website.
Imaging Endpoints (IE) is an imaging research and core laboratory that provides comprehensive imaging CRO (iCRO) services and technology solutions throughout the clinical trial process. IE is one of the largest iCROs globally, the largest focused in oncology, and is widely recognized for conducting central imaging for the industry’s most notable regulatory approvals.
IE’s experience spans hundreds of successful trials across all phases of development, including many of the most high-profile, global registration trials and regulatory approvals in the industry. IE also accelerates product development by integrating new, more powerful technologies into clinical trials such as CD8 imaging, radiomics, and artificial intelligence where peer-reviewed publications have established the company as the industry leader.
Imaging Endpoints is headquartered in Scottsdale, AZ, with offices in Cambridge, MA; London, UK; Leiden, Netherlands; Basel, Switzerland; Hyderabad, India and Shanghai, China. IE is an affiliate of HonorHealth, one of the largest healthcare systems nationally, and an affiliate of Southwest Medical Imaging, Ltd. (SMIL/RadPartners), part of the largest private radiology group in the U.S.
Contact: slofland@imagingendpoints.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/imaging-endpoints-expands-leadership-in-big-data-analysis-radiomics-and-ai-301568206.html
SOURCE Imaging Endpoints
AI Model Designed to Guarantee Accuracy & Avoid HallucinationsPALO ALTO, Calif.--(BUSINESS WIRE)--Harmonic, an artificial intelligence…
DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine and NI Medical are pleased to announce they will be presenting a…
The project, which leverages HealthPartners myGenetics community research database, will help primary care clinicians provide…
BANGALORE, India, June 10, 2024 /PRNewswire/ -- Drug Discovery Informatics Market is Segmented by Type (Software, Services), by…
Commemorating 40 years of providing exceptional home health care, Special Touch Home Care launches www.CDPAS.com geared…
JERSEY CITY, N.J., June 10, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release…